Selected invited talks, panels, fireside chats, and writing on viral vector CMC, engineered capsids, and the path to first-in-human.
Field-tested perspectives for the developers, founders, and investors who have to make these decisions in real time, on real budgets.
Where AI-designed and rationally engineered AAV capsids break the platform assumptions early teams quietly rely on — and what to do about it before it costs your program a quarter.
Capsid access is the start, not the finish. A sponsor-side playbook for sequencing the chain of CMC, manufacturing, and development decisions between capsid in hand and IND submission.
A combination of peer-reviewed work in molecular virology and industry-facing writing on CMC strategy. Full publication list available on request.